Regeneron Pharmaceuticals, Inc.

-7.34 (-0.98%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)81.26B
Current PE19.43
Forward PE 17.64
2yr Forward PE 16.94
See more stats
Estimates Current Quarter
Revenue$3.06 Billion
Adjusted EPS$10.29
See more estimates
10-Day MA$741.47
50-Day MA$779.63
200-Day MA$739.98
See more pivots

Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 11851


Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.